Showing results (21-30 of 133) with videos related to

Sort By:
Pageof 14
Antimicrobial Agents and Chemotherapy|October 22, 2008
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034)Mike Flint, Stanley Mullen, Anne M Deatly, et al.
The Pediatric Infectious Disease Journal|September 25, 2012
The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trialRosalyn Singleton, Jay Wenger, Joseph A Klejka, et al.
Scientific Reports|October 28, 2014
Toward a more accurate view of human B-cell repertoire by next-generation sequencing, unbiased repertoire capture and single-molecule barcodingLinling He, Devin Sok, Parisa Azadnia, et al.
Nature Chemical Biology|July 9, 2013
Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodiesMohammed N Amin, Jason S McLellan, Wei Huang, et al.
Trends in Immunology|April 29, 2020
Improving Vaccine-Induced Immunity: Can Baseline Predict Outcome?John S Tsang, Carlota Dobaño, Pierre VanDamme, et al.
Retrovirology|June 17, 2016
Association of mutations in V3/C3 domain with enhanced sensitivity of HIV-1 clade C primary envelopes to autologous broadly neutralizing plasma antibodiesSuprit Deshpande, Shilpa Patil, Rajesh Kumar, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 11, 2010
Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1Robert Pejchal, Laura M Walker, Robyn L Stanfield, et al.
The Pediatric Infectious Disease Journal|April 16, 2013
Immunogenicity, safety and tolerability of 3 lots of 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in the United StatesTerry Payton, Douglas Girgenti, Robert W Frenck, et al.
The Pediatric Infectious Disease Journal|October 11, 2011
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccineRobert Frenck, Allison Thompson, Sylvia H Yeh, et al.
Human Vaccines & Immunotherapeutics|March 1, 2014
Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trialChristine Juergens, Pierre J T de Villiers, Keymanthri Moodley, et al.
Pageof 14